Biolinq Raises $58M for Intradermal Glucose Sensor Pivotal Trial

Biolinq has finished a $58 million financing round to support a U.S. pivotal clinical trial for its intradermal glucose sensor and subsequent U.S. Food and Drug Administration (FDA) submission.
 
Biolinq’s wearable patch has an array of tiny, electrochemical sensors that measure glucose levels from the intradermal space just beneath the skin’s surface. It combines glucose information with relative levels of activity in one device, according to the company.
 
The patch is placed on the upper forearm with a clear line of sight. It incorporates an intuitive display on the device that informs when glucose levels are in a target range and when they’re elevated beyond the healthy range. Biolinq said the sensor array on a silicon chip were designed for redundancy, reliability, and multi-analyte capabilities.

 
“Our technology approach enables access to a coveted, metabolically active compartment of the skin for biosensing without the use of introducer needles or bleeding,” said Rich Yang, CEO of Biolinq. “Over the past decade, our team has been pioneering a new biosensor platform designed to inform and inspire, with a mission to reach more people that are in need of simple solutions to improve metabolic health.”
 
The latest funding round was led by global investment company Alpha Wave Ventures.
 
“Companies that disrupt entire industries often don’t originate from a single discipline,” said Rick Gerson, chairman of Alpha Wave Global. “Biolinq has attracted leading experts in biosensor development, consumer electronics design, proprietary materials science, software engineering and semiconductor manufacturing to build a new category of biowearables. Biolinq is well-positioned to enter the market with a differentiated solution for people living with diabetes.”

Find more information about glucose sensing technology here!